Apheon, a pan-European mid-market private equity investor, is pleased to announce that it has acquired a majority stake in Longwood (“Longwood”, or the “Group”), a renowned Spanish distributor and provider of high value-added In-Vitro Diagnostics (“IVD”) equipment, solutions and services for public and private hospitals and laboratories. Mr. Antonio Raichs, the founder and Chairman, will remain invested in the business and support the continued acceleration  of Longwood’s development under the leadership of CEO Mr. Miguel Giralt.

Founded in 1992 by Mr. Raichs and headquartered in Zaragoza, Spain, Longwood has grown into a distributor of reference and a key player within the most innovative IVD technologies, partnering with a high-quality base of OEMs. Longwood’s solutions are primarily structured around “Next Generation Sequencing” technology, covering various core therapeutic areas, including transplant, genetics, oncology, and forensic genetics, among others. The Group’s unique business model is further rounded with specific divisions manufacturing niche proprietary products and providing in-house value-added services addressing a diversified and recurrent client base of public and private hospital laboratories primarily in Spain and Portugal. Under the vision and leadership of Mr. Raichs and Mr. Giralt, CEO since 2020, Longwood has built a reputation of combining a high value add portfolio of solutions together with an outstanding team of qualified professionals committed to providing excellent service.

Apheon has a longstanding track record of backing entrepreneurial founders and families across Europe, successfully scaling their companies internationally. Leveraging its experience of having done so in similar industries in the past, Apheon will provide Longwood with strategic guidance and capital for growth, with the goal to further expand its product offering and solutions within key therapeutic areas, also pursuing meaningful M&A to build a strong platform in Spain and abroad. Mr. Raichs and Mr. Giralt will both significantly reinvest into the Group, remaining fully committed for this new chapter of growth alongside Apheon.

Mr. Antonio Raichs, Founder and Chairman, commented, “In Apheon, I believe we found the best partner to further unlock our ambitions to grow our group and presence. We particularly appreciate their track record of partnering with founders, including having already successfully done so in similar industries in the past. We are aligned on the vision and with their partnership and expertise, we will accelerate Longwood’s growth and international development”.

Mr. Miguel Giralt, CEO, said, “We see significant potential to scale and position Longwood to meet the evolving needs of our clients, sustaining our strong focus on customer care and service quality. Through the many interactions and conversations over the past year, we believe Apheon will be a great partner, and I am delighted to have their support”.

Mr. Pablo Álvarez Couso, Partner at Apheon, added: “As entrepreneurs ourselves, we recognized Longwood’s focus on innovation and excellence, and have been impressed by its strong historical development and management team. It is a privilege to have the trust of Antonio and Miguel and the opportunity to work alongside them to bring their vision forward. The Group has evolved significantly in the past years through exceptional service and innovations, and I am confident that we can achieve our plan together”.

About Longwood:
Longwood is a reference high value-added distribution platform of IVD solutions and services for both public and private hospital laboratories. Headquartered in Zaragoza (Spain), the Group creates solutions for its clients by combining a broad range of third-party IVD equipment and test kits sourced from blue-chip international OEMs through its main operating company: Diagnóstica Longwood. The Group’s offering is centred around Next Generation Sequencing but complemented by a broad range of diagnostic technologies used across several therapeutic areas. The Group rounds its value proposition with the manufacture of niche proprietary products through BDR and in-house value-added laboratory services provided through Citogen. For more information, please visit www.dlongwood.com.

About Apheon:
Apheon is a pan-European mid-market private equity investment company managing ~€3 billion of assets from select global institutional investors and families. Apheon is characterized by its partnership approach, providing “patient and friendly capital” and industrial know-how to entrepreneurs and management teams, preparing their companies for the future. Through its pan-European footprint, the firm acts as a gateway into Europe for companies in the mid-market. Since its founding in 2005, Apheon has raised more than €3.5 billion in capital, invested in ~40 companies across Europe and completed ~200 add-on acquisitions for a total aggregate transaction value in excess of €7 billion. Apheon’s current portfolio consists of 21 companies across its target sectors, representing ~€3 billion sales and 22,000 employees. Apheon is advised by Apheon Advisors which has offices in Brussels, Milan, Madrid, Paris, Munich and Amsterdam. For more information, please visit www.apheon.com.

+++

For more information, please contact:

John Mansvelt, COO, Apheon
jm@apheon.com
T: +32 2 213 60 90

Natalia Yek, Head of Investor Relations, Apheon
ny@apheon.com
T: +39 340 18 29 313

 

London, 15 July 2025 – Advent, a leading global private equity investor, today announces the sale of its stake in DONTE GROUP, Spain’s leading dental platform, to Ontario Teachers’ Pension Plan Board (“Ontario Teachers’”), a global investor with a strong track record in the dental and healthcare sectors.

Since investing in DONTE in 2019, Advent has helped to transform the business into Spain’s largest oral healthcare platform. Under Advent’s stewardship, DONTE grew from a single-brand business with 150 clinics into a diversified, multi-brand leader comprising over 400 clinics across four leading brands – Vitaldent, Maex, Moonz, and Smysecret. The company has treated around 1 million patients during this time, while investing more than €40 million in clinical quality and over €35m in technological innovation, enhancing patient experience.

Ontario Teachers’ is a global investor with over CAD$266 billion in net assets and a history of strong investments in healthcare, with a global healthcare portfolio of CAD$6 billion, including Heartland Dental, PhyNet, Veonet and NVISON. The investment underscores Ontario Teachers’ confidence in DONTE’s growth trajectory and its mission to provide outstanding patient care.

Tom Allen, Managing Director at Advent, said, “We are incredibly proud to have supported the DONTE team over the past six years in building an outstanding dental platform with a relentless focus on patient care and medical excellence.”

Gonzalo Santos, Managing Director at Advent, added, “This milestone validates DONTE’s position as a market leader in Spain and sets the stage for its continued success. We are confident that Ontario Teachers’ is the ideal partner to support DONTE in its next chapter.”

Javier Martín, CEO of DONTE GROUP, said, “We are grateful for Advent’s partnership, which has been instrumental in scaling DONTE into a leading oral health platform. We look forward to this next phase of growth with Ontario Teachers’ as we expand our presence and continue delivering cutting-edge care to our patients, and we are pleased to partner with an investor with deep expertise in the sector.”

Advent has developed significant expertise and an extensive track record investing in the healthcare sector. Over the past 30 years, Advent has completed more than 50 investments across over 15 countries in areas including pharma services, medtech, healthcare services, and life sciences. Advent is committed to partnering with healthcare businesses to scale innovation, improve patient outcomes, and deliver sustainable growth.

The transaction is subject to customary regulatory approvals and its closing is expected to take place in Q4 2025.

Advent was advised by J.P. Morgan as lead financial advisor and J&A Garrigues, S.L.P. As lead legal advisor.

Media Contacts
Peter Folland
pfolland@adventinternational.co.uk

About Advent
Advent is a leading global private equity investor committed to working in partnership with management teams, entrepreneurs, and founders to help transform businesses. With 16 offices across five continents, we oversee more than USD $91 billion in assets under management* and have made 430 investments across 44 countries.

Since our founding in 1984, we have developed specialist market expertise across our five core sectors: business & financial services, consumer, healthcare, industrial, and technology. This approach is bolstered by our deep sub-sector knowledge, which informs every aspect of our investment strategy, from sourcing opportunities to working in partnership with management to execute value creation plans. We bring hands-on operational expertise to enhance and accelerate businesses.

As one of the largest privately-owned partnerships, our 660+ colleagues leverage the full ecosystem of Advent’s global resources, including our Portfolio Support Group, insights provided by industry expert Operating Partners and Operations Advisors, as well as bespoke tools to support and guide our portfolio companies as they seek to achieve their strategic goals.

To learn more, visit our website or connect with us on LinkedIn.

*Assets under management (AUM) as of December 31, 2024. AUM includes assets attributable to Advent advisory clients as well as employee and third-party co-investment vehicles.

About DONTE GROUP
DONTE GROUP is Spain’s largest dental platform, offering comprehensive oral care through its portfolio of leading brands: Vitaldent, Maex, Moonz, and Smysecret. With over 400 clinics and more than 8.5 million patients treated over more than 35 years, DONTE is at the forefront of medical excellence and patient-centric care.

Transaction Advances Company’s ‘Three-S’ Plan to Streamline its Portfolio and Strengthen Focus on its ‘High-Grow’ Brands

 

Total Consideration of Up to €327 Million, Consisting of €300 Million in Upfront Cash and Up to €27 Million in Potential Future Milestone Payments

 

Expected Net Proceeds to be Directed Towards Previously Announced Capital Allocation Priorities, Including Further Strengthening the Company’s Balance Sheet

 

 

Dublin, Ireland – [July 14], 2025 – Perrigo Company plc (NYSE: PRGO) (“Perrigo” or the “Company”), a leading global provider of Consumer Self-Care Products, today announced it has signed an agreement with Kairos Bidco AB, an investment vehicle managed by KKR, a leading global investment firm, to sell the Company’s Dermacosmetics branded business for up to €327 million, including €300 million in upfront cash and up to an additional €27 million contingent on the achievement of net sales milestones over the next three years. This transaction advances the Company’s Three-S plan to Stabilize, Streamline and Strengthen the organization, honing its strategic focus to invest in its ‘high-grow’, high-return opportunities. Trusted brands within this proposed transaction include ACO, Biodermal, Emolium and Iwostin.

“This transaction marks another significant milestone in the execution of our ‘Three-S’ plan,” said Patrick Lockwood-Taylor, President and Chief Executive Officer. “By sharpening our focus on core self-care categories that align with our One Perrigo model, we are enhancing our ability to drive sustainable growth and deliver greater value to consumers, customers and shareholders. We believe these brands are well-positioned to thrive under new ownership, where they can benefit from dedicated focus and investment.”

Inaki Cobo, Partner at KKR, said, “We are pleased to announce the acquisition of Perrigo’s Dermacosmetics business, home to trusted brands and high-quality products. We’ve been impressed by the talented team behind its success and the strong and loyal market reputation they’ve built. This acquisition aligns with KKR’s strategy of investing in resilient, growth-oriented consumer health platforms. We look forward to working closely with the management team to accelerate growth by leveraging our global network, operational expertise, and long-term capital, unlocking lasting value in this dynamic and important sector.”

Expected net proceeds from the transaction would be directed towards previously announced capital allocation priorities, including further strengthening the Company’s balance sheet and supporting long-term value creation.

This transaction is expected to close in the first quarter of 2026, subject to customary closing conditions, including regulatory approvals and consultation with works council. In calendar year 2024, Perrigo’s Dermacosmetics branded business generated approximately €125 million in net sales and approximately 5% of Perrigo’s 2024 adjusted operating income.

Advisors

Greenhill & Co., an affiliate of Mizuho, is serving as financial advisor to Perrigo and Latham & Watkins is serving as legal advisor.

About Perrigo 

Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.

Perrigo’s unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill^®, Mederma^®, Compeed^®, EllaOne^®, and Jungle Formula^®.

For more information, visit www.perrigo.com.

 

About KKR

KKR is a leading global investment firm with approximately $664 billion in assets under management as of March 31, 2025. KKR invests globally across private equity, credit and real assets like infrastructure and real estate, and also offers capital markets and insurance solutions. KKR follows a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and the communities in which they operate.

KKR has deep expertise across consumer health and beauty products, with recent investments including category leaders such as Karo Healthcare (subject to closing), The Bountiful Company, Wella Company, Coty, Vini Cosmetics, KDC/ONE, and Arnott’s Group.

KKR is acquiring Perrigo’s Dermacosmetics branded business through its Core Private Equity strategy.

For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com.

 

Non-GAAP Measures

 

This press release contains certain non-GAAP measures. A “non-GAAP financial measure” is defined as a numerical measure of a company’s financial performance that excludes or includes amounts different from the most directly comparable measure calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) in the statements of operations, balance sheets or statements of cash flows of the Company. Pursuant to the requirements of the U.S. Securities and Exchange Commission, the Company has provided reconciliations to the most directly comparable U.S. GAAP measures for the non-GAAP financial measures referred to in this press release.

These non-GAAP financial measures should be considered as supplements to the GAAP reported measures, should not be considered replacements for, or superior to the GAAP measures and may not be comparable to similarly named measures used by other companies.

 

Perrigo Forward-Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “forecast,” “predict,” “potential” or the negative of those terms or other comparable terminology.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including our ability to complete the proposed divestment of the Dermacosmetics branded business, receipt of Works Councils and regulatory approval regarding the transaction, performance by counterparties to the transaction and the likelihood of satisfying the deferred payment milestones associated with the transaction, among others. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2024 and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Perrigo Contact

 

Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications,

(269) 686-3373, E-mail: bradley.joseph@perrigo.com

Nicholas Gallagher, Senior Manager, Global Investor Relations & Corporate Communications,

(269) 686-3238, E-mail: nicholas.gallagher@perrigo.com

 

KKR Contact

 

Annabel Arthur, Head of EMEA Corporate Communications,

+44 7554 919 491, E-mail: annabel.arthur@kkr.com

TABLE I

PERRIGO COMPANY PLC

RECONCILIATION OF NON-GAAP MEASURE

(in millions)

(unaudited)

	Twelve Months Ended December 31, 2024
Consolidated Continuing Operations	Net Sales		Operating Income
Reported	$                4,373.4		$                           112.9
As a % of reported net sales			2.6  %
Pre-tax adjustments:
Amortization expense related primarily to acquired intangible assets			229.5
Restructuring charges and other termination benefits			113.4
Unusual litigation			54.2
Impairment charges(1)			88.9
Infant formula remediation			21.7
Gain on divestitures and investment securities			(28.1)
Other(2)			16.0
Adjusted Operating Income			$                           608.5
As a % of reported net sales			13.9  %
Adjusted Operating Income in Euros(3)			€                         562.60

(1) During the twelve months ended December 31, 2024, we determined the carrying value of the Rare Diseases reporting unit net assets exceeded their fair value less costs to sell, resulting in a total impairment charge of $34.1 million, inclusive of a goodwill impairment charge of $22.1 million, we also determined the carrying value of the Hospital & Specialty Business net assets exceeded their fair value less costs to sell, resulting in a total impairment charge of $16.2 million, inclusive of a goodwill impairment charge of $5.4 million and we determined the carrying value of our Prevacid^® branded product was impaired by $38.6 million and recorded the charge within our CSCA segment. During the twelve months ended December 31, 2023, we determined goodwill related to our Rare Diseases reporting unit was impaired by $90.0 million and recorded the charge within our CSCI segment.

(2) Other pre-tax adjustments for the twelve months ended December 31, 2024 include expenses of $14.4 million related to de-designation of interest rate swap agreements, amounts related to professional consulting fees for divestiture activity and amounts related to a foreign jurisdiction transfer tax payment. Other pre-tax adjustments for the twelve months ended December 31, 2023 include $2.3 million related to professional consulting fees for potential divestitures, $2.0 million related to an Irish VAT settlement and $0.8 million related to a foreign jurisdiction transfer tax payment.

(3) Adjusted Operating Income was translated at the average exchange rate for the 2024 calendar year of 0.9245 EUR per USD.

 

Download PDF

TEAM Technologies, an Arlington Capital Partners Portfolio Company, Expands Medical Device Manufacturing Capabilities with Acquisition of Duke Empirical, Inc.

Washington, D.C. and Knoxville, TN – July 7, 2025 – Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company TEAM Technologies (“TEAM Tech”), a leading end-to-end outsourced manufacturer of mission-critical medical devices, has acquired another leader in the sector, Duke Empirical, Inc (“Duke”). Based in Morgan Hill, CA., Duke is a leading designer, developer and manufacturer of advanced medical devices for interventional cardiovascular applications. Duke specializes in the design and manufacture of innovative catheters and minimally invasive delivery systems.

TEAM Tech works with blue-chip healthcare customers and medical device OEMs to provide end-to-end outsourced design and manufacturing services for critical medical devices, enabling customers to streamline their supply chains and reduce delivery lead times. With synergistic production capabilities and customer bases, the acquisition of Duke will further complement TEAM’s turnkey offering for healthcare and MedTech OEMs, enabling accelerated manufacturing at scale for complex Class II / III medical devices and delivery systems.

“Our investment in TEAM Tech reflects Arlington’s focus on building businesses that deliver mission critical solutions in complex, regulated end markets. The addition of Duke expands TEAM Tech’s ability to serve leading healthcare and MedTech OEMs in the fastest growing segments of the medical device market, while enhancing its capabilities to develop and manufacture highly advanced devices that support the delivery of life saving medical procedures,” said Matt Altman, a Managing Partner at Arlington Capital Partners.

“When we began our partnership with Arlington, we knew we had an opportunity to accelerate our growth and expand our offerings to best serve our clients,” said Marshall White, President and CEO of TEAM Tech. “Duke adds complementary capabilities and greater capacity to our already robust portfolio of full-service medical device manufacturing solutions, and will enable us to provide a greater breadth of complete solutions for our customer partners, who are doing critical, lifesaving work across the healthcare field.”

“The acquisition of Duke enhances TEAM Tech’s capabilities by furthering its expertise in designing and manufacturing advanced interventional cardiovascular products as well as polymer extrusion,” said Gordon Auduong, Managing Director at Arlington Capital Partners. “We are excited to partner with the exceptional team at Duke to deliver TEAM Tech’s entire portfolio of capabilities to further support our customers’ growth.”

Arlington has an extensive track record of building leading companies in highly regulated industries that are critical to the USA’s healthcare infrastructure, government systems and national security. Within healthcare, Arlington focuses on working with businesses that save lives, improve the delivery of products and services and reduce costs for patients and providers. Other notable recent healthcare sector investments the firm has made include Riverpoint Medical, Millstone Medical Outsourcing, Grand River Aseptic Manufacturing, Everest Clinical Research, Afton Scientific and AVS Bio.

Houlihan Lokey served as financial advisor and Goodwin Procter LLP served as legal advisor to TEAM Tech and Arlington Capital Partners.

 

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private investment firm specializing in government-regulated industries. The firm partners with founders and management teams to build strategically important businesses in the healthcare, government services and technology, and aerospace and defense sectors. Since its inception in 1999, Arlington has invested in over 175 companies and is currently investing out of its $3.8 billion Fund VI. For more information, visit Arlington’s website at www.arlingtoncap.com and follow Arlington on LinkedIn.

 

About TEAM Technologies

Headquartered in Knoxville, TN, with facilities throughout the United States and international facilities in Mexico and Singapore, TEAM Technologies is a specialized end-to-end outsourced manufacturer of mission-critical, single-use medical devices. The company has an extensive array of advanced and vertically integrated manufacturing solutions servicing top medical device and pharmaceutical OEMs. With its deep industry experience and reputation for the highest quality standards, TEAM Technologies leverages seamless, turnkey processes and innovation to dramatically simplify and improve its customers’ supply chains. For more information, visit teamtech.com.

 

About Duke Empirical, Inc.

Headquartered in Morgan Hill, CA, Duke Empirical is a leading developer and manufacturer of innovative medical devices focused on advanced catheters and minimally invasive delivery systems. The company specializes in medical device design and development, precision custom extrusion, high performance catheter manufacturing, medical device component assembly, and finished goods assembly and packaging. For more information, visit dukeempirical.com.

 

Gilde Healthcare today announces the combined private equity investments in Artinis Medical Systems (Netherlands) and NIRx Medical Technologies (Germany/United States), both pioneers in functional Near-Infrared Spectroscopy (fNIRS) solutions. This dual transaction brings together two highly complementary companies, establishing a new global leader in fNIRS.

Advancing fNIRS technology
Functional Near-Infrared Spectroscopy is a differentiated neuroimaging technology that offers unique advantages over traditional brain imaging methods such as fMRI and EEG. The technology offers scientists a new perspective on understanding the functions of the human brain, enabling, high-impact, neuroscience research worldwide. With its strong scientific foundation in basic research, fNIRS is increasingly adopted in applied research environments, unlocking its potential in therapeutic areas such as neurodegenerative diseases, mental health, stroke rehabilitation and developmental neuroscience.

Joining forces for innovation
Artinis and NIRx, both recognized as market leaders with superior technology and support, will continue to operate from their current locations and under their existing brand names. The founders and current management teams of both companies remain actively involved. The newly formed group will leverage its complementary product offerings, shared expertise, integrated R&D, and increased scale to accelerate innovation and commercial growth.

The shared vision is to develop the newly formed group in the go-to platform for neuroimaging- and related research tools while driving innovation across (multi-)modalities. The new platform aims to enhance the adoption of fNIRS in applied neuroscience by setting industry standards, and by making the technology more accessible to academic researchers globally. Apart from organic growth, the group will pursue additional add-on acquisitions in line with this vision.

Gilde’s entrepreneurial investment strategy to drive better care at lower cost
This transaction exemplifies Gilde Healthcare’s entrepreneurial investment strategy, which focuses on partnering with founders and managers to accelerate growth and develop organizations in attractive healthcare niches.  The investment via two parallel transactions was executed in a proprietary setting, leveraging Gilde’s own developed investment thesis, broad network and deep expertise in the research tools sector.

By combining Artinis and NIRx, Gilde Healthcare enables the formation of a global market leader with the ability to fuel ground-breaking neuroscience research that addresses the growing complexity and prevalence of brain-related conditions. This ultimately contributes to better care and lower cost for the healthcare system.

Willy Colier, co-founder and CEO of Artinis, commented: “Roeland, my co-founder, and I are proud of Artinis’ journey over the past 24 years. We have built a company known for its great products, fantastic people, and satisfied customers. Joining forces with NIRx is an exciting step that will enhance the value we provide to both our current and future customers. We look forward to this new phase as we leverage our combined scale and expertise, benefiting from the support of Gilde Healthcare. “

Patrick Britz, CEO of NIRx, commented: “Constant innovation has made functional near-infrared spectroscopy a rapidly growing and highly productive solution for neuroscience. Now, with the strong support of Gilde Healthcare, two highly skilled teams, NIRx and Artinis, are joining forces to accelerate these advancements. I am genuinely thrilled about the possibilities this partnership unlocks, fNIRS is just at its beginning.”

Boyd Rutten, Investment Director at Gilde Healthcare, commented: “These parallel transactions are an excellent example of our entrepreneurial investment strategy. By bringing both companies together, we are creating a platform that will lead innovation and makes brain imaging tools more accessible to researchers globally. We want to thank the founders of Artinis and NIRx for their trust and express our excitement about working together going forward.”         

Completion of the transaction is subject to regulatory approval.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.